Vascular Therapies, Inc.   Report issue

For profit Phase 3
Founded: Cresskill NJ United States (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2015
NCT02513303
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Vascular Therapies, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

sirolimus (rapamune) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteriovenous Fistula (Phase 3)

Fistula (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1